Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
Abstract Purpose: HER2 (or ERBB2) aberrations, including both amplification and mutations,
have been classified as oncogenic drivers that contribute to 2% to 6% of lung …
have been classified as oncogenic drivers that contribute to 2% to 6% of lung …
[HTML][HTML] Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
S Liu, S Li, J Hai, X Wang, T Chen… - … cancer research: an …, 2018 - ncbi.nlm.nih.gov
Purpose: HER2 (or ERBB2) aberrations, including both amplification and mutations, have
been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas …
been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas …
Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
S Liu, S Li, J Hai, X Wang, T Chen, MM Quinn… - Clinical Cancer …, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: HER2 (or ERBB2) aberrations,
including both amplification and mutations, have been classified as oncogenic drivers that …
including both amplification and mutations, have been classified as oncogenic drivers that …
Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.
S Liu, S Li, J Hai, X Wang, T Chen… - … Cancer Research: an …, 2018 - europepmc.org
Purpose: HER2 (or ERBB2) aberrations, including both amplification and mutations, have
been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas …
been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas …
Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
S Liu, S Li, J Hai, X Wang, T Chen, MM Quinn, P Gao… - 2018 - kms.shanghaitech.edu.cn
摘要Purpose: HER2 (or ERBB2) aberrations, including both amplification and mutations,
have been classified as oncogenic drivers that contribute to 2% to 6% of lung …
have been classified as oncogenic drivers that contribute to 2% to 6% of lung …
Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
S Liu, S Li, J Hai, X Wang, T Chen… - … : an official journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose: HER2 (or ERBB2) aberrations, including both amplification and mutations, have
been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas …
been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas …